#elbasvir

Lack of familiarity with the drug and the availability of competing therapies are probably the reason for its quiet reception so far.

Merck’s investigational hepatitis C treatment grazoprevir/elbasvir cured high rates of the virus among individuals coinfected with HIV.

Highlights from presentations at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco.

Individuals who have failed hepatitis C treatment may ultimately achieve a cure if they add Sovaldi (sofosbuvir) to a subsequent treatment reg...

Elbasvir/grazoprevir cured high rates of individuals with genotypes 1, 4 or 6 of hepatitis C who inject drugs and are receiving opioid agonist...

Merck’s grazoprevir, MK-3682, and either elbasvir or MK-8408, given for eight weeks, cured high rates of people with genotypes 1, 2 and 3 of h...

Two new treatments have hit the market, offering more options for those with genotypes 3 and 4, while another new regimen for multiple genotyp...

In recent trials Harvoni, Viekira Pak and grazoprevir/elbasvir all cured high rates of hepatitis C among those coinfected with HIV.

Merck has filed a new drug application with the U.S. Food and Drug Administration (FDA) for approval of its single-tablet hepatitis C...

Highlights from the 50th Annual Meeting of the European Association for the Study of the Liver include treatments that benefit a wider...

Eight weeks of Merck’s grazoprevir/elbasvir, plus Gilead Science’ Sovaldi cured high rates of people with genotype 1 or 3 of hepatitis C.

Twelve weeks of Merckâ€™s grazoprevir and elbasvir, plus ribavirin, cured nearly all treatment-experienced people with genotype 1 of hepa...

Merckâ€™s grazoprevir/elbasvir, given with or without ribavirin, cured over 90 percent of various subgroups of people with hepatitis C, i...

12 weeks of Merckâ€™s grazoprevir and elbasvir cured hepatitis C in 99 percent of people with genotype 1 of the virus and advanced kidney...

Merck’s fixed-dose hepatitis combination tablet, grazoprevir/elbasvir, has received two “breakthrough therapy” designations from the FDA.